Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
10,741.35-177.35
Stock Analysis, IPO, Mutual Funds, Bonds & More

Biocon board approves sale of branded formulations business to subsidiary

The Board of Directors in its meeting approved the sale of Branded Formulations India (BFI) business to Biocon Biologics India (BBIL).

PTI|
Jun 17, 2019, 09.31 PM IST
0Comments
BCCL
Kiran-Mazumdar-bccl
(Kiran Mazumdar Shaw , Chairman & managing Director , Biocon Limited )
Pharma firm Biocon Monday said it will sell Branded Formulations India (BFI) business on a 'going concern' basis to its subsidiary Biocon Biologics India Ltd for Rs 45 crore.

The Board of Directors in its meeting approved the sale of Branded Formulations India (BFI) business to Biocon Biologics India (BBIL), the pharma company said in a BSE filing.

"The transfer of BFI business on slump sale basis will lead to consolidation of marketing and manufacturing activities relating to BFI business under a single entity with common leadership and achieve synergies/value accretion for the group," Biocon said.

The company has fixed July 1, 2019, as the expected date of completion of the sale and the consideration to be received is Rs 45 crore.
0Comments

Also Read

Suresh Subramanian to head Biocon's branded formulations biz

Accor launches low-cost brand 'Formule1' in Ahmedabad

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service